Inocras and IMBdx Announce Strategic Partnership to Transform Cancer Patient Care in the U.S.
May 22 2024 - 8:00AM
Business Wire
Inocras and IMBdx have announced a partnership aimed at
enhancing care for cancer patients in the U.S. Through this
partnership, Inocras, a leader in whole genome sequencing
diagnostics, and IMBdx, an innovator in liquid biopsy-based
diagnostics for cancer, will be able to provide broader offerings
for cancer patients and their providers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240522093513/en/
L to R: Jehee Suh, CEO of Inocras,
Tae-You Kim, CEO of IMBdx (Photo: Business Wire)
Inocras specializes in cancer profiling using whole genome
sequencing (WGS), capturing over 99% of an individual's genomic
makeup. This allows for a broader analysis of mutations and complex
variations, allowing for deeper insights into a patient's
condition. IMBdx has developed a comprehensive portfolio of liquid
biopsies for the cancer diagnosis and treatment cycle. The company
was recently listed on the KOSDAQ in South Korea.
The partnership will focus on Inocras providing IMBdx’s liquid
biopsy-based cancer diagnostics in the U.S. market, creating
alternatives for patients and their providers when genetic testing
from tissue biopsy is not feasible. This joint initiative
introduces a new model of patient care, leveraging advanced two
technologies in genetic testing - whole genome data and liquid
biopsy.
"Our collaboration with IMBdx marks a significant step forward
in our mission to transform healthcare for cancer and rare disease
patients," said Jehee Suh, CEO of Inocras. "We think of patients at
the core and are trying to create more options for patients and
providers. By combining our strengths, we're not just delivering
advanced diagnostic services, we're contributing to creating a
pathway to a more effective cancer care journey.”
About Inocras Inc:
Inocras Inc. (formerly Genome Insight, Inc) is a pioneering
provider of whole genome sequencing and analytics for cancer and
rare diseases. The company is dedicated to unlocking the potential
of genomic data to enable precision health for everyone. For more
information about Inocras and our services, please visit
Inocras.com.
About IMBdx:
IMBdx is at the forefront of liquid biopsy technology,
developing advanced diagnostic tools that capture and analyze
circulating biomarkers to detect and monitor diseases more
effectively and non-invasively.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522093513/en/
Sohee Cho / media@inocras.com